Portfolio expansion StoneCalibre has a track record of acquiring and divesting technology and life sciences assets across multiple jurisdictions (Los Angeles, Paris, London) with a focus on buy-and-build and special situations, signaling opportunities to pitch scalable tech integrations, platform plays, and cross-border investment services.

Tech portfolio The firm demonstrates active technology portfolio development through past acquisitions (AVST, HNT assets) and collaboration with tech partners, presenting sales angles for IT modernization, UC software, diagnostics tech, and unified communications capabilities.

Growth potential Revenue range reported at 10–25 million suggests a mid-market footprint with room for strategic add-ons, efficiency improvements, and scale opportunities via portfolio synergies, making StoneCalibre a target for growth capital, optimization tools, and integration services.

Global reach With offices in the US and Europe and a history of cross-border investments, there are opportunities to offer international due diligence services, cross-border M&A support, and localized go-to-market strategies for portfolio company acquisitions.

Operational leverage Past partnerships in life sciences and diagnostics indicate appetite for operational resources and strategic guidance; a solution set around post-acquisition integration, performance improvement, and supply chain optimization could address their core value creation needs.